<DOC>
	<DOCNO>NCT00542451</DOCNO>
	<brief_summary>The purpose study find effect postoperative combination therapy : trastuzumab ( herceptin ) paclitaxel ( taxol ) breast cancer recurrence . A combination trastuzuamb chemotherapy use woman node positive high risk node negative disease . This test utilizes well tolerated regimen weekly paclitaxel trastuzumab woman T1 , node negative tumor HER2 positive . We would like determine effective drug combination use woman early stage breast cancer , well good define side effect treatment .</brief_summary>
	<brief_title>Adjuvant Paclitaxel Trastuzumab Node-Negative HER2-Positive Breast Cancer</brief_title>
	<detailed_description>- Participants enroll study time start adjuvant therapy breast cancer . Participants receive chemotherapy paclitaxel every week 12 week . They begin receive trastuzumab time begin paclitaxel . Once complete 12 week paclitaxel trastuzumab , receive trastuzumab every 3 week weekly 40 week . - Participants follow routine assessment physical exam vital sign every 3 month first year , every 6 month year 2-5 . Then would like keep track participant medical condition call telephone per year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm invasive carcinoma breast Tumors must less equal 3cm great dimension Must nodenegative breast cancer accord teh AJCC 7th edition ER/PR determination require . ER PRassays perform immunohistochemical method HER2 positive : IHC 3+ FISH &gt; 2 Bilateral breast cancer individually meet eligibility criterion allow Patients tumor tissue available , tissue block sufficient size make 15 slide must send DFCI test Less equal 84 day mastectomy axillary dissection sentinel node biopsy patient 's extensive breast surgery breastsparing procedure All tumor remove either modified radical mastectomy segmental mastectomy ( lumpectomy ) , either sentinel node biopsy axillary dissection 18 year age old ECOG Performance Status 0 1 Adequate bone marrow function , hepatic function , renal function outline protocol Left ventricular ejection fraction great equal 50 % Willingness discontinue hormonal agent prior registration study Willingness discontinue sex hormonal therapy , e.g . birth control pill , prior registration study Patients history ipsilateral DCIS eligible treat wideexcision alone , without radiation therapy Patients undergoing breast conservation therapy must contraindications radiation therapy Pregnant nursing woman Locally advance tumor diagnosis , include tumor fix chest wall , peau d'orange , skin ulcerations/nodules , clinical inflammatory change History prior chemotherapy past 5 year History prior trastuzumab therapy Active , unresolved infection Prior history malignancy past 5 year , except early stage tumor skin cervix treat curative intent Sensitivity benzyl alcohol Grade 2 great neuropathy per NCI 's CTCAv3.0 . ( Exception : Any chronic neurologic disorder look casebycase basis study chair ) . Active cardiac disease outline protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>node-negative breast cancer</keyword>
	<keyword>HER-2 positive</keyword>
</DOC>